The pharmacological up-regulation of FXN gene expression is a therapeutic approach for the treatment of FRDA that directly addresses the primary issue of frataxin deficiency rather than secondary disease effects. Here, FXN is linked to hyperinsulinemic hypoglycemia, familial, 4.